Bristol-Meyers Beats Q3 Expectations with Opdivo

Tuesday, October 27, 2015

Source: FiercePharma

Bristol-Myers Squibb ($BMY) expects big things from its immunotherapy powerhouse Opdivo, pushing for expanded indications for the med as it competes for the top spot in the field. Now the company is celebrating the fruits of its labor, beating third quarter estimates with strong sales of its PD-1 inhibitor--not to mention a standout performance from its hep C franchise.

View All News »